Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The Gyros^TM immunoassay platform brings increased productivity and efficiency to the development of biotherapeutics and vaccines. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and to meet increasing regulatory demands on testing.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nanoliter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company has around 60 employees, based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe, and a growing network of distributors.

 The Gyros^TM immunoassay platform brings increased productivity and efficiency to the development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and to meet increasing regulatory demands on testing. Spanning the entire spectrum of immunoassays, the platform accelerates assay development, minimizes sample consumption and cuts the time to result. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The Gyros^TM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.